Beaumont RE, Cordery P, James LJ, Watson P. Supplementation with a low-dose of octopamine does not influence endurance cycling performance in recreationally active men. J Sci Med Sport. 2017;20(10):952-956. View abstract.
Beaumont RE, Cordery P, James LJ, Watson P. Supplementation with a low-dose of octopamine does not influence endurance cycling performance in recreationally active men. J Sci Med Sport. 2017;20(10):952-956. View abstract.
Bucci L, Chiaverelli R. Hepatic encephalopathy EEG and octopamine. J Clin Psychiatry. 1980;41(5):175-7. View abstract.
Bucci L, Chiaverelli R. Hepatic encephalopathy EEG and octopamine. J Clin Psychiatry. 1980;41(5):175-7. View abstract.
Bunzow JR, Sonders MS, Arttamangkul S, et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol. 2001;60(6):1181-8. View abstract.
Bunzow JR, Sonders MS, Arttamangkul S, et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol. 2001;60(6):1181-8. View abstract.
Carpéné C, Galitzky J, Fontana E, Atgié C, Lafontan M, Berlan M. Selective activation of beta3-adrenoceptors by octopamine: comparative studies in mammalian fat cells. Naunyn Schmiedebergs Arch Pharmacol. 1999;359(4):310-21. View abstract.
Carpéné C, Galitzky J, Fontana E, Atgié C, Lafontan M, Berlan M. Selective activation of beta3-adrenoceptors by octopamine: comparative studies in mammalian fat cells. Naunyn Schmiedebergs Arch Pharmacol. 1999;359(4):310-21. View abstract.
D'Andrea G, Granella F, Leone M, Perini F, Farruggio A, Bussone G. Abnormal platelet trace amine profiles in migraine with and without aura. Cephalalgia. 2006;26(8):968-72. View abstract.
D'Andrea G, Granella F, Leone M, Perini F, Farruggio A, Bussone G. Abnormal platelet trace amine profiles in migraine with and without aura. Cephalalgia. 2006;26(8):968-72. View abstract.
D'Andrea G, Nordera G, Pizzolato G, et al. Trace amine metabolism in Parkinson's disease: low circulating levels of octopamine in early disease stages. Neurosci Lett. 2010;469(3):348-51. View abstract.
D'Andrea G, Nordera G, Pizzolato G, et al. Trace amine metabolism in Parkinson's disease: low circulating levels of octopamine in early disease stages. Neurosci Lett. 2010;469(3):348-51. View abstract.
D'Andrea G, Terrazzino S, Leon A, et al. Elevated levels of circulating trace amines in primary headaches. Neurology 2004;62:1701-5. View abstract.
D'Andrea G, Terrazzino S, Leon A, et al. Elevated levels of circulating trace amines in primary headaches. Neurology 2004;62:1701-5. View abstract.
David JC, Coulon JF, Delacour J. Behavioural and neurochemical effects of intracerebroventricular administrations of p-octopamine in rats. Brain Res. 1982 10;241(2):299-306. View abstract.
David JC, Coulon JF, Delacour J. Behavioural and neurochemical effects of intracerebroventricular administrations of p-octopamine in rats. Brain Res. 1982 10;241(2):299-306. View abstract.
Fontana E, Morin N, Prévot D, Carpéné C. Effects of octopamine on lipolysis, glucose transport and amine oxidation in mammalian fat cells. Comp Biochem Physiol C Toxicol Pharmacol. 2000;125(1):33-44. View abstract.
Fontana E, Morin N, Prévot D, Carpéné C. Effects of octopamine on lipolysis, glucose transport and amine oxidation in mammalian fat cells. Comp Biochem Physiol C Toxicol Pharmacol. 2000;125(1):33-44. View abstract.
Health Canada. Synephrine, Octopamine and Caffeine Health Risk Assessment (HRA) Report. Approved May 16, 2011. Accessed November 6, 2019. Available at: https://www.nutratechinc.com/advz/Studies2011/Safety/S1%20Health%20Canada%200511.pdf.
Health Canada. Synephrine, Octopamine and Caffeine Health Risk Assessment (HRA) Report. Approved May 16, 2011. Accessed November 6, 2019. Available at: https://www.nutratechinc.com/advz/Studies2011/Safety/S1%20Health%20Canada%200511.pdf.
Mercader J, Wanecq E, Chen J, Carpéné C. Isopropylnorsynephrine is a stronger lipolytic agent in human adipocytes than synephrine and other amines present in Citrus aurantium. J Physiol Biochem. 2011;67(3):443-52. View abstract.
Mercader J, Wanecq E, Chen J, Carpéné C. Isopropylnorsynephrine is a stronger lipolytic agent in human adipocytes than synephrine and other amines present in Citrus aurantium. J Physiol Biochem. 2011;67(3):443-52. View abstract.
Nespoli A, Bevilacqua G, Staudacher C, Rossi N, Salerno F, Castelli MR. Pathogenesis of hepatic encephalopathy and hyperdynamic syndrome in cirrhosis. Role of false neurotransmitters. Arch Surg. 1981;116(9):1129-38. View abstract.
Nespoli A, Bevilacqua G, Staudacher C, Rossi N, Salerno F, Castelli MR. Pathogenesis of hepatic encephalopathy and hyperdynamic syndrome in cirrhosis. Role of false neurotransmitters. Arch Surg. 1981;116(9):1129-38. View abstract.
Pawar RS, Grundel E. Overview of regulation of dietary supplements in the USA and issues of adulteration with phenethylamines (PEAs). Drug Test Anal 2017;9:500-517. View abstract.
Pawar RS, Grundel E. Overview of regulation of dietary supplements in the USA and issues of adulteration with phenethylamines (PEAs). Drug Test Anal 2017;9:500-517. View abstract.
Penzak SR, Jann MW, Cold JA, et al. Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults. J Clin Pharmacol 2001;41:1059-63. View abstract.
Penzak SR, Jann MW, Cold JA, et al. Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults. J Clin Pharmacol 2001;41:1059-63. View abstract.
Smedema JP, Müller GJ. Coronary spasm and thrombosis in a bodybuilder using a nutritional supplement containing synephrine, octopamine, tyramine and caffeine. S Afr Med J. 2008;98(5):372-3. View abstract.
Smedema JP, Müller GJ. Coronary spasm and thrombosis in a bodybuilder using a nutritional supplement containing synephrine, octopamine, tyramine and caffeine. S Afr Med J. 2008;98(5):372-3. View abstract.
Thevis M, Koch A, Sigmund G, Thomas A, Schänzer W. Analysis of octopamine in human doping control samples. Biomed Chromatogr. 2012;26(5):610-5. View abstract.
Thevis M, Koch A, Sigmund G, Thomas A, Schänzer W. Analysis of octopamine in human doping control samples. Biomed Chromatogr. 2012;26(5):610-5. View abstract.
U.S. Food & Drug Administration. Dietary supplement ingredient advisory list. https://www.fda.gov/food/dietary-supplement-products-ingredients/dietary-supplement-ingredient-advisory-list. Accessed September 19, 2019.
U.S. Food & Drug Administration. Dietary supplement ingredient advisory list. https://www.fda.gov/food/dietary-supplement-products-ingredients/dietary-supplement-ingredient-advisory-list. Accessed September 19, 2019.
Visentin V, Morin N, Fontana E, et al. Dual action of octopamine on glucose transport into adipocytes: inhibition via beta3-adrenoceptor activation and stimulation via oxidation by amine oxidases. J Pharmacol Exp Ther 2001;299:96-104. View abstract.
Visentin V, Morin N, Fontana E, et al. Dual action of octopamine on glucose transport into adipocytes: inhibition via beta3-adrenoceptor activation and stimulation via oxidation by amine oxidases. J Pharmacol Exp Ther 2001;299:96-104. View abstract.
Zhao J, Wang M, Avula B, Khan IA. Detection and quantification of phenethylamines in sports dietary supplements by NMR approach. J Pharm Biomed Anal. 2018;151:347-355. View abstract.
Zhao J, Wang M, Avula B, Khan IA. Detection and quantification of phenethylamines in sports dietary supplements by NMR approach. J Pharm Biomed Anal. 2018;151:347-355. View abstract.